MedPath

CICERI FABIO

🇮🇹Italy
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:2
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Not Applicable
1 (33.3%)

A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma

Not Applicable
Not yet recruiting
Conditions
Smoldering Multiple Myeloma (SMM)
First Posted Date
2025-07-17
Last Posted Date
2025-07-22
Lead Sponsor
Ciceri Fabio
Target Recruit Count
62
Registration Number
NCT07069751

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

Recruiting
Conditions
Acute Myeloid Leukemia
First Posted Date
2024-08-02
Last Posted Date
2025-05-08
Lead Sponsor
Ciceri Fabio
Target Recruit Count
80
Registration Number
NCT06535113
Locations
🇮🇹

GOM Bianchi Melacrino Morelli, Reggio Calabria, Calabria, Italy

🇮🇹

IRCCS Ospedale San Raffaele, Milan, Italy

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

Recruiting
Conditions
Acute Myeloid Leukemia, in Relapse
First Posted Date
2021-11-17
Last Posted Date
2025-05-13
Lead Sponsor
Ciceri Fabio
Target Recruit Count
500
Registration Number
NCT05124288
Locations
🇮🇹

IRCCS Ospedale San Raffaele, Milan, Milano, Italy

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Transplant-Related Hematologic Malignancy
Interventions
Procedure: Peripheral Blood Stem Cell Transplant
First Posted Date
2019-05-23
Last Posted Date
2023-11-18
Lead Sponsor
Ciceri Fabio
Target Recruit Count
15
Registration Number
NCT03961919
Locations
🇮🇹

Ospedale San Raffaele, Milano, Lombardia, Italy

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

Phase 2
Completed
Conditions
Graft Vs Host Disease
Transplant-Related Hematologic Malignancy
Leukemia, Acute
Fungal Infection
Myelodysplastic Syndromes
Interventions
Drug: Conditioning treatment "Thiotepa-Treosulfan-Fludarabine"
Procedure: PBSC graft
Drug: GvHD prophylaxis
Drug: Primary antifungal prophylaxis
First Posted Date
2018-02-15
Last Posted Date
2022-07-19
Lead Sponsor
Ciceri Fabio
Target Recruit Count
10
Registration Number
NCT03434704
Locations
🇮🇹

Ospedale San Raffaele, Milano, Lombardia, Italy

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.